Rockwell Medical (RMTI) Competitors

ReShape Lifesciences (NASDAQ:RSLS) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Does the media prefer RSLS or RMTI?

In the previous week, ReShape Lifesciences had 2 more articles in the media than Rockwell Medical. MarketBeat recorded 6 mentions for ReShape Lifesciences and 4 mentions for Rockwell Medical. ReShape Lifesciences' average media sentiment score of 0.19 beat Rockwell Medical's score of -0.75 indicating that ReShape Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ReShape Lifesciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rockwell Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Is RSLS or RMTI more profitable?

Rockwell Medical has a net margin of -0.27% compared to ReShape Lifesciences' net margin of -48.26%. Rockwell Medical's return on equity of -0.90% beat ReShape Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-48.26%	-251.90%	-59.49%
Rockwell Medical	-0.27%	-0.90%	-0.47%

Do analysts prefer RSLS or RMTI?

Rockwell Medical has a consensus target price of $4.00, suggesting a potential upside of 366.20%. Given Rockwell Medical's stronger consensus rating and higher possible upside, analysts plainly believe Rockwell Medical is more favorable than ReShape Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rockwell Medical	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Do institutionals & insiders have more ownership in RSLS or RMTI?

22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are owned by institutional investors. 0.0% of ReShape Lifesciences shares are owned by insiders. Comparatively, 3.6% of Rockwell Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has preferable valuation & earnings, RSLS or RMTI?

Rockwell Medical has higher revenue and earnings than ReShape Lifesciences. Rockwell Medical is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$8.01M	0.72	-$7.13M	-$193.23	-0.01
Rockwell Medical	$101.49M	0.29	-$480K	-$0.02	-42.90

Which has more risk and volatility, RSLS or RMTI?

ReShape Lifesciences has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Summary

Rockwell Medical beats ReShape Lifesciences on 13 of the 17 factors compared between the two stocks.